Invesaro

Stocks Health care CRIS

NASDAQ · Health care

Curis Inc (CRIS)

Curis Inc brought in $4.3M of revenue over the twelve months to June 30, 2026, down 62.2% from a year earlier. It posted a net loss of $21.2M. At June 30, 2026 it held $5.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch CRIS in 60 seconds
Price
$0.83
-5.62% on the day · September 25, 2026
52-week range $0.81 to $34.80
Market cap
$1.7M
Revenue (last 12 months)
$4.3M
-62.2% year on year
Net margin
-490.3%

What Curis Inc does

Curis Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRIS.

Revenue and profit by year

Revenue
FY18: $10.4M $10.4M FY18FY19: $10M $10M FY19FY20: $10.8M $10.8M FY20FY21: $10.6M $10.6M FY21FY22: $10.2M $10.2M FY22FY23: $10M $10M FY23FY24: $10.9M $10.9M FY24FY25: $9.4M $9.4M FY25
Net income
FY18: -$32.6M -$32.6M FY18FY19: -$32.1M -$32.1M FY19FY20: -$29.9M -$29.9M FY20FY21: -$45.4M -$45.4M FY21FY22: -$56.7M -$56.7M FY22FY23: -$47.4M -$47.4M FY23FY24: -$43.4M -$43.4M FY24FY25: -$7.6M -$7.6M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$9.4M-$5.7M-$7.6M-$0.58n/a
2024$10.9M-$44.5M-$43.4M-$6.88n/a
2023$10M-$48.3M-$47.4M-$8.96-$38.4M
2022$10.2M-$53M-$56.7M-$12.14-$54.8M
2021$10.6M-$42.1M-$45.4M$0.50-$37.6M
2020$10.8M-$24.9M-$29.9M-$0.61-$26.4M

Full financial statements: income, balance sheet and cash flow

Where CRIS ranks in Health care

Revenue$9.4M
#476 of 646 in Health care · Bottom 26%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Curis Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$4.02 versus -$13.61.
  2. August 13, 2026
  3. August 10, 2026
  4. July 30, 2026
  5. July 2, 2026
  6. July 1, 2026
  7. July 1, 2026
  8. June 25, 2026
  9. June 5, 2026
  10. May 22, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 9, 2026. Insider transactions on SEC

Insider trades

What the people running Curis Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns CRIS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Nantahala Capital Management, LLC13G, passive with 2 related filers 9.99% 4,215,165 April 24, 2026
Stonepine Capital Management, LLC13G, passive with 3 related filers 9.9% 4,025,992 March 27, 2026
Thomas A. Satterfield, Jr.13G, passive 9.9% 3,957,950 May 14, 2026
Nantahala Capital Partners Limited Partnership13G, passive 6.98% 2,944,000 April 7, 2026

Latest filings below 5%: Armistice Capital, LLC 4.99% (May 15, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CRIS

What does Curis Inc do?

Curis Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRIS.

Is Curis Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $21.2M on revenue of $4.3M.

How much revenue does Curis Inc make?

Over the twelve months to June 30, 2026 Curis Inc reported revenue of $4.3M. That is 62.2% less than a year earlier.

When did Curis Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

Compare CRIS with

Compare CRIS with any company

Follow CRIS

Get an email when Curis Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow CRIS: get an email when it files

Where the numbers come from

Financial figures are the values Curis Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.